Stephan Witte
Hennigsdorf, BB 16761, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial.
Journal: Journal of critical care
Published: January 24, 2025
Enhancing sepsis biomarker development: key considerations from public and private perspectives.
Journal: Critical care (London, England)
Published: May 03, 2024
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
Journal: BMJ open
Published: July 08, 2021
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
Journal: Intensive care medicine
Published: February 10, 2020
Establishing a model of primary bovine hepatocytes with responsive growth hormone receptor expression.
Journal: Journal of dairy science
Published: October 18, 2018
A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
Journal: British journal of clinical pharmacology
Published: August 14, 2017
Illustrating the formation of metal nanoparticles with a growth concept based on colloidal stability.
Journal: Physical chemistry chemical physics : PCCP
Published: July 14, 2015
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
Journal: Annals of the rheumatic diseases
Published: May 08, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026